Bayer and the Broad Institute of MIT and Harvard have extended their research collaboration an additional five years to develop and advance innovative cancer treatments. The expanded agreement will focus on joint cancer target identification and discovery of new therapeutic approaches in oncology. Established in 2013, the collaboration combines the Broad Institute’s expertise in cancer research and chemical biology with Bayer’s in-depth experience in small, chemically manufactured molecules a...